AbbVie Submits Cariprazine FDA Application for Major Depressive Disorder

Article

The Supplemental New Drug Application was based on the results of numerous clinical trials.

AbbVie has officially submitted a Supplemental New Drug Application (sNDA) to the US Food and Drug Administration (FDA) for cariprazine (VRAYLAR) as an adjunctive treatment for major depressive disorder (MDD).

The potential indication would be specifically for patients who are receiving ongoing antidepressant therapy.

Clinical Program

The application was based on the results of several clinical trials, including the phase 3 Study 311-301-001, RGH-MD-75, and RGH-MD-76.

In 311-301-001, the treatment resulted in a clinically and statistically significant change in the Montgomery-Asberg Depression Rating Scale (MADRS) toral score from baseline to week 6 in patients treated with cariprazine 1.5 mg daily compared to placebo.

In the RGH-MD-75 registration enabling study, cariprazine also showed a clinically and statistically significant change in MADRS total score from baseline to week 8 in patients treated with cariprazine 2-4.5 mg per day compared to placebo.

Finally, the RGH-MD-76 study also examined the long-term safety and tolerability of the drug over 26 weeks.

Safety and the Future

The studies show a safety profile consistent with the safety profile of cariprazine for other indications, including for the treatment of adults with depressive, acute manic, and mixed episodes associated with bipolar I disorder and schizophrenia.

"Many people living with major depressive disorder struggle to find a treatment that reduces their depressive symptoms, with many taking years to find the right treatment,” Michael Severino, MD, vice chairman and president, AbbVie, said in a statement. “Cariprazine, when added to ongoing antidepressant treatment in patients with major depressive disorder, demonstrated that it can reduce depressive symptoms.”

Related Videos
Boadie Dunlop, MD, Weighs in on FDA Advisory Vote on Lykos’ MDMA
Bhanu Prakash Kolla, MBBS, MD: Treating Sleep with Psychiatric Illness
Awaiting FDA Decision on MDMA Assisted Therapy, with Bessel van der Kolk, MD
Bessel van der Kolk, MD: The Future of MDMA Assisted Therapy in PTSD
Bessel van der Kolk, MD: What MDMA-Assisted Therapy Taught us About PTSD
Why Are Adult ADHD Cases Climbing?
Aaron Henry, PA-C, MSHS: Regaining Black Male Patient Trust in the Doctor's Office
Depression Screening: Challenges and Solutions at the Primary Care Level
Danielle O'Laughlin, PA-C, MS: Navigating Long-Term Risks, Family Planning in PCOS
HCPLive Five at APA 2024 | Image Credit: HCPLive
© 2024 MJH Life Sciences

All rights reserved.